Mirna Therapeutics, Inc.-Product Pipeline Review-2015

Mirna Therapeutics, Inc.-Product Pipeline Review-2015

  • Products Id :- GMDHC06840CDB
  • |
  • Pages: 34
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Mirna Therapeutics, Inc.-Product Pipeline Review-2015


Global Markets Direct's, 'Mirna Therapeutics, Inc.-Product Pipeline Review-2015', provides an overview of the Mirna Therapeutics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Mirna Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Mirna Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Mirna Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Mirna Therapeutics, Inc.'s pipeline products

Reasons To Buy

Evaluate Mirna Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Mirna Therapeutics, Inc. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Mirna Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Mirna Therapeutics, Inc. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Mirna Therapeutics, Inc.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Mirna Therapeutics, Inc. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Mirna Therapeutics, Inc. Snapshot 5

Mirna Therapeutics, Inc. Overview 5

Key Information 5

Key Facts 5

Mirna Therapeutics, Inc.-Research and Development Overview 6

Key Therapeutic Areas 6

Mirna Therapeutics, Inc.-Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products-Monotherapy 10

Pipeline Products-Combination Treatment Modalities 11

Pipeline Products-Partnered Products 12

Partnered Products/Combination Treatment Modalities 13

Mirna Therapeutics, Inc.-Pipeline Products Glance 14

Mirna Therapeutics, Inc.-Clinical Stage Pipeline Products 14

Phase I Products/Combination Treatment Modalities 14

Mirna Therapeutics, Inc.-Early Stage Pipeline Products 15

Preclinical Products/Combination Treatment Modalities 15

Discovery Products/Combination Treatment Modalities 16

Mirna Therapeutics, Inc.-Drug Profiles 17

MRX-34 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

let-7 + miR-34 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

miR-Rx06 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

miR-Rx07 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

mIR-Rx16 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

miR-Rxlet-7 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

Mirna Therapeutics, Inc.-Pipeline Analysis 25

Mirna Therapeutics, Inc.-Pipeline Products by Target 25

Mirna Therapeutics, Inc.-Pipeline Products by Route of Administration 26

Mirna Therapeutics, Inc.-Pipeline Products by Molecule Type 27

Mirna Therapeutics, Inc.-Recent Pipeline Updates 28

Mirna Therapeutics, Inc.-Dormant Projects 31

Mirna Therapeutics, Inc.-Locations And Subsidiaries 32

Head Office 32

Appendix 33

Methodology 33

Coverage 33

Secondary Research 33

Primary Research 33

Expert Panel Validation 33

Contact Us 33

Disclaimer 34

List of Tables

Mirna Therapeutics, Inc., Key Information 5

Mirna Therapeutics, Inc., Key Facts 5

Mirna Therapeutics, Inc.-Pipeline by Indication, 2015 8

Mirna Therapeutics, Inc.-Pipeline by Stage of Development, 2015 9

Mirna Therapeutics, Inc.-Monotherapy Products in Pipeline, 2015 10

Mirna Therapeutics, Inc.-Combination Treatment Modalities in Pipeline, 2015 11

Mirna Therapeutics, Inc.-Partnered Products in Pipeline, 2015 12

Mirna Therapeutics, Inc.-Partnered Products/ Combination Treatment Modalities, 2015 13

Mirna Therapeutics, Inc.-Phase I, 2015 14

Mirna Therapeutics, Inc.-Preclinical, 2015 15

Mirna Therapeutics, Inc.-Discovery, 2015 16

Mirna Therapeutics, Inc.-Pipeline by Target, 2015 25

Mirna Therapeutics, Inc.-Pipeline by Route of Administration, 2015 26

Mirna Therapeutics, Inc.-Pipeline by Molecule Type, 2015 27

Mirna Therapeutics, Inc.-Recent Pipeline Updates, 2015 28

Mirna Therapeutics, Inc.-Dormant Developmental Projects,2015 31

List of Figures

Mirna Therapeutics, Inc.-Pipeline by Top 10 Indication, 2015 7

Mirna Therapeutics, Inc.-Pipeline by Stage of Development, 2015 9

Mirna Therapeutics, Inc.-Monotherapy Products in Pipeline, 2015 10

Mirna Therapeutics, Inc.-Partnered Products in Pipeline, 2015 12

Mirna Therapeutics, Inc.-Pipeline by Top 10 Target, 2015 25

Mirna Therapeutics, Inc.-Pipeline by Top 10 Route of Administration, 2015 26

Mirna Therapeutics, Inc.-Pipeline by Top 10 Molecule Type, 2015 27

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

Current R&D Portfolio of Mirna Therapeutics, Inc.; Mirna Therapeutics, Inc. - Key Therapeutics; Mirna Therapeutics, Inc. - Pipeline Overview and Promising Molecules; Mirna Therapeutics, Inc. - News; Mirna Therapeutics, Inc. - Latest Updates; Mirna Therapeutics, Inc. - Pipeline; Mirna Therapeutics, Inc. - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 101625
Site License
USD 3000 INR 203250
Corporate User License
USD 4500 INR 304875



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com